[A chemotherapy regimen including CDDP in patients with bronchogenic carcinoma--a comparison between bronchial artery infusion and intravenous administration].

Forty patients with lung cancer were treated using two methods. One was transbronchial artery infusion (BAI) of CDDP and the other was intravenous administration of CDDP with VDS, ACNU or etoposide. There was no difference in response rate between the two groups. The response rate was higher in patients with squamous cell carcinoma compared to these with adenocarcinoma. Compared with the combination group, BAI patients had fewer adverse effects, such as myelosuppression, alopecia, nausea and vomiting. Thus, it was concluded that CDDP is very effective for patients with lung cancer and that CDDP administered by BAI is useful for hilar-type squamous cell carcinoma.